Envision the tomorrow of cancer therapy with innovative and new challenges
Involved in the establishment of the company as a founding member of Chordia Therapeutics in November 2017 after engaging in drug discovery research in the oncology area at a pharmaceutical company.
We are conducting research and development on completely novel anti-cancer drugs. If the process from research and development to marketing of a new drug is divided into 10 steps, we are responsible for steps 1 through 5 or 6. I am in charge of the initial conceptualization of new drugs to be developed, and I conduct research and development based on this concept. Currently under research and development is an oral anti-cancer drug. We are conducting research and development every day with our reliable colleagues with the desire to “deliver effective new drugs to patients suffering from cancer as quickly as possible”.
Moreover, I am also involved in management as a CSO. As the CEO’s right-hand man, I am responsible for strategy planning and execution, and focus on promoting research and development with a sense of speed.
Up until now in Japan, a single pharmaceutical company has been responsible for all processes from research and development to marketing of new drugs. However, in the past five years, the number of startup companies (startup ventures) that are solely in the field of research and development has been increasing, and our company is one of them.
The advantage of working at Chordia Therapeutics is undeniably the speed of decision-making. We come up with our own concepts for new drugs, and as soon as the path we believe in is set, we immediately begin to research and strive toward our goals. For large companies, innovation and novelty are often seen as a risk, but it is no exaggeration to say that being able to tackle new challenges with a sense of speed is a researcher's best friend. There is a sense of mission and satisfaction every day in being able to work with a small group of elite colleagues with a spirit of challenge.
Cultivating seeds for new medicines and taking on the challenge of developing attractive new anti-cancer medicines.
Joined Chordia Therapeutics in May 2018 after engaging in pharmacological research mainly in the areas of lifestyle-related diseases and oncology at a pharmaceutical company.
I conduct pharmacological research to evaluate whether compounds synthesized based on the concept of new drug development properly act on the target and exert therapeutic effects. It is my job to examine and nurture the “seeds” in the preliminary stage of a drug, so to speak, to see if they are able to develop into a new drug or not. In addition to pharmacological research, I also conduct drug safety evaluations and search for biomarkers that can be applied to clinical studies.
In addition to experiments, we have many interactions outside the company, for example, communicating with joint research partners such as academia and subcontractors who have requested evaluation, as well as report writing, project management, and a wide variety of other tasks.
Although the same drug discovery research may have been conducted by a large organization, it would have often taken time to plan and make decisions on the execution of each study. But at Chordia Therapeutics, we are quick to make decisions, and when we have a concept, we get the go ahead immediately, so we can focus solely on the direction we want to go. On the other hand, drug discovery research is the preliminary stage of drug research, so things often do not go as expected. However, we do not see this as a negative as it is in our company culture to quickly change our thinking to “how can we make this work?” and move forward.
Cancer research is a job that involves human life and death. I face my work each day with the hope that cultivating the seeds of new medicines will lead to human lives and contribute to society.
Creating new avenues to improve the lives of patients.
Joined Chordia Therapeutics in February 2022 after an academic career researching infectious diseases and childhood cancers.
I am currently part of the Medical Science department where I lead the development of clinical trial strategies and information dissemination, contributing to the overall development of Chordia. In addition, I continue to improve the quality of our clinical development by obtaining cutting-edge medial information and by discussing with Japanese and American doctors who directly treat patients. Prior to the Medical Science department, I also was a Research member where I was the project leader for one of our pre-clinical pipelines. I utilize my experience as an academic researcher to bridge both pre-clinical and clinical data to drive the strategy of our clinical trials. The main goal of drug development is getting our medication into the hands of patients, so I work towards this goal by creating strong, medically significant clinical trials.
Since childhood, I have always wanted to help others. Initially, I wanted to become a medical doctor to treat patients directly. However, I chose a career in research to potentially impact millions through innovative treatments. As drug discovery researchers, success is not only measured by the novelty of the drug’s mechanisms, but by the ability to heal and provide new hope for patients.
At Chordia, our diverse team consists of experts and dreamers who share a common goal: healing patients. This collective mentality fosters effective communication and collaboration across all our departments. Drug development is a team effort, and working at Chordia has allowed me to grow alongside colleagues who prioritize the team and support each other. Together, we will strive to deliver new medicines and a brighter future for patients.
We are looking for people who are willing to fight cancer together with patients and contribute to the creation of a society that has hope for tomorrow.
If you are interested in working at Chordia, please inquire through our form.
